Literature DB >> 11915985

Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial.

Julia C Senges1, Ruediger Becker, Kirsten D Schreiner, Alexander Bauer, Slawomir Weretka, Karl Siegler, Wolfgang Kuebler, Wolfgang Schoels.   

Abstract

In the MADIT study, a selected group of postinfarction patients with asymptomatic nonsustained ventricular tachycardia (NSVT) has been shown to benefit from prophylactic ICD treatment. The present study analyzed the variability of NSVT in a patient population fulfilling the non-invasive MADIT criteria. Three consecutive Holter ECGs were performed in weekly intervals in 68 postinfarction patients with an LVEF < or = 0.35. Patients with NSVT underwent programmed ventricular stimulation (PVS); patients were implanted with an ICD if sustained VT or VF was inducible. If NSVT was found in at least two recordings, the arrhythmia was defined as reproducible. In 28 (41%) of the 68 patients, NSVT was found in at least one recording. Seventeen patients revealed NSVT in the first, the remaining 11 in the second registration; no patient had NSVT only in the third Holter. Of the patients with NSVT, 50% had only one, 39% had two, and 11% had three positive recordings. Thus, reproducible NSVT was found in only 50% of the patients with NSVT. Predictors for reproducibility were LVEF > 0.27, NYHA Class I, absence of digitalis therapy, and > 2 NSVT per 24-hour period. Reproducible NSVT was not associated with risk factors such as elevated mean heart rate, reduced heart rate variability, late potentials, or inducibility of sustained VT during PVS. During 17 +/- 9 months of follow-up, seven (10%) patients experienced arrhythmic events: two without and five with previously documented NSVT. In the latter patients, first occurrence of NSVT was consistently in the first Holter; only two of them had reproducible NSVT. In postinfarction patients, the risk factor NSVT exhibits marked spontaneous variability, especially in those with a low number of NSVT per 24-hour period, LVEF < 0.27 or NYHA III, which limits its clinical value as a selection criterion for PVS. Reproducibility of NSVT itself does not seem to be an independent risk factor.

Entities:  

Mesh:

Year:  2002        PMID: 11915985     DOI: 10.1046/j.1460-9592.2002.00183.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  6 in total

Review 1.  Electrocardiographic predictors of arrhythmic death.

Authors:  Michael G McLaughlin; Peter J Zimetbaum
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-10       Impact factor: 1.468

2.  Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity.

Authors:  Yukitaka Shizukuda; Dorothy J Tripodi; Gloria Zalos; Charles D Bolan; Yu-Ying Yau; Susan F Leitman; Myron A Waclawiw; Douglas R Rosing
Journal:  Am J Cardiol       Date:  2011-12-22       Impact factor: 2.778

Review 3.  Nonsustained ventricular tachycardia in dilated cardiomyopathy.

Authors:  Frank A Cuoco; Steven N Singh
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

4.  Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events.

Authors:  Tobias Simon; Ruediger Becker; Frederik Voss; Olympia Bikou; Melanie Hauck; Manuela Licka; Hugo A Katus; Alexander Bauer
Journal:  Clin Res Cardiol       Date:  2008-01-14       Impact factor: 5.460

Review 5.  Prevalence and incidence of arrhythmias and sudden death in heart failure.

Authors:  John G F Cleland; Sudipta Chattopadhyay; Aleem Khand; Timothy Houghton; Gerald C Kaye
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

6.  Prognostic significance of non-sustained ventricular tachycardia on stored electrograms in pacemaker recipients.

Authors:  Gianluigi Bencardino; Francesco Raffaele Spera; Gaetano Pinnacchio; Francesco Perna; Maria Lucia Narducci; Gianluca Comerci; Gemma Pelargonio; Francesca Augusta Gabrielli; Giulio La Rosa; Gaetano Antonio Lanza; Filippo Crea
Journal:  PLoS One       Date:  2019-11-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.